Source Photo: Promomed
Marketed as Semaltara, the medication is approved for treating adults with type 2 diabetes mellitus. According to the State Register of Medicines, it will be available in 3 mg, 7 mg, and 14 mg strengths, packaged either as blister packs (three cards of 10 tablets each) or bottles of 30 tablets.
Until now, Russia's only registered oral semaglutide product was Rybelsus from Novo Nordisk. This domestic alternative provides patients with expanded access to GLP-1 therapy without requiring daily injections.
The global pipeline for GLP-1 receptor agonists remains robust. The FDA is currently reviewing Novo Nordisk's application for an oral formulation of Wegovy. Additionally, in September 2025, Swedish biotech company Orexo released preclinical data on an intranasal semaglutide delivery system.
Russia has approved multiple GLP-1 agonists, including semaglutide, liraglutide, dulaglutide, and exenatide. According to RNC Pharma analytics, the Russian obesity treatment market reached $231.5 million in sales during 2024.
Source: State Register of Medicines